Y-F Liaw

Author PubWeight™ 11.62^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma.	Gut	2007	1.76
2	Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.	J Viral Hepat	2007	1.20
3	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.	J Viral Hepat	2012	1.09
4	Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.	Br J Cancer	2012	0.95
5	Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.	Aliment Pharmacol Ther	2007	0.94
6	Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?	Int J Obes (Lond)	2006	0.90
7	Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.	J Viral Hepat	2006	0.84
8	Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area.	Oncogene	2006	0.83
9	High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.	Gut	2005	0.82
10	Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.	J Viral Hepat	2004	0.79
11	Acute leukaemia in chronic hepatitis B patients with lamivudine therapy.	Int J Clin Pract	2004	0.79
12	Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion.	J Viral Hepat	2011	0.76